Prediction of the response to peg-interferon-alfa in patients with HBeAG positive chronic hepatitis B using decline of HBV DNA during treatment

Journal of Medical Virology

Volumn 82, Issue 7, 2010, Pages 1135-1142

  Hansen, Bettina E ^a   Buster, Erik H C J ^a   Steyerberg, Ewout W ^a   Lesaffre, Emmanuel ^a,b   Janssen, Harry L A ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b KU LEUVEN   (Belgium)

Author keywords

Antiviral therapy; Dynamic prediction; HBV DNA decline; Hepatitis B virus; PEG IFN; Response

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; PEGINTERFERON; PEGINTERFERON ALPHA2B; VIRUS DNA; ALPHA INTERFERON; ALPHA2B INTERFERON; ANTIVIRUS AGENT; BIOLOGICAL MARKER; MACROGOL DERIVATIVE; RECOMBINANT PROTEIN;

ADULT; ARTICLE; CONTROLLED STUDY; DNA DETERMINATION; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; TREATMENT RESPONSE; VIRUS LOAD; BLOOD; DRUG ADMINISTRATION; HEPATITIS B, CHRONIC; PREDICTIVE VALUE; TREATMENT OUTCOME;

HEPATITIS B VIRUS;

ADULT; ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; DNA, VIRAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HEPATITIS B, CHRONIC; HUMANS; INTERFERON-ALPHA; MALE; POLYETHYLENE GLYCOLS; PREDICTIVE VALUE OF TESTS; RECOMBINANT PROTEINS; TREATMENT OUTCOME;

EID: 77954412012     PISSN: 01466615     EISSN: 10969071     Source Type: Journal    
DOI: 10.1002/jmv.21778     Document Type: Article

References (23)

1. Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL. 2008. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology 135:459-467.
2. Buster EH, Hansen BE, Lau KE, Piratvisuth T, McCloud PI, Button P, Steyerberg EW, Zeuzem S, Janssen HL. 2009. Prediction of response to peginterferon-alha in HBeAg positive chronic hepatitis B:Amodel based on 721 patients. Gastroenterology 137:2002-2009.
3. Cooksley WG, Piratvisuth T, Lee SD, Mahachai V, Chao YC, Tanwandee T, Chutaputti A, Chang WY, Zahm FE, Pluck N. 2003. Peginterferon alpha-2a (40 kDa): An advance in the treatment of hepatitis B e antigen-positive chronic hepatitis B. J Viral Hepat 10:298-305.
4. Dahari H, Shudo E, Ribeiro RM, Perelson AS. 2009. Modeling complex decay profiles of hepatitis B virus during antiviral therapy. Hepatology 49:32-38.
5. EASL Clinical Practice Guidelines. 2009. Management of chronic hepatitis B. European association for the study of the liver. J Hepatol 50:227-242.
6. Flink HJ, Buster EH, Merican I, Nevens F, Kitis G, Cianciara J, de Vries RA, Hansen BE, Schalm SW, Janssen HL. 2007. Relapse after treatment with peginterferon alpha-2b alone or in combination with lamivudine in HBeAg positive chronic hepatitis B. Gut 56:1485-1486.
7. Fried MW, Piratvisuth T, Lau GK, Marcellin P, Chow WC, Cooksley G, Luo KX, Paik SW, Liaw YF, Button P, Popescu M. 2008. HBeAg and hepatitis B virus DNA as outcome predictors during therapy with peginterferon alfa-2a for HBeAg-positive chronic hepatitis B. Hepatology 47:428-434.
8. Hernan MA, Brumback B, Robins JM. 2000. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology (Cambridge, Mass) 11:561-570. (Pubitemid 30660035)
9. Janssen HL, Buster EH. 2009. Comments on the EASL practice guidelines for the management of chronic hepatitis B: Controversies in interferon-based therapy. J Hepatol 51:224-226.
10. Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Niesters HG, Zondervan P, Hansen B, Schalm SW. 2005. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: A randomised trial. Lancet 365:123-129.
11. Lau GK, Piratvisuth T, Luo KX, Marcellin P, Thongsawat S, Cooksley G, Gane E, Fried MW, Chow WC, Paik SW, Chang WY, Berg T, Flisiak R, McCloud P, Pluck N. 2005. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 352:2682-2695.
12. Liaw YF, Sung JJ, Chow WC, Farrell G, Lee CZ, Yuen H, Tanwandee T, Tao QM, Shue K, Keene ON, Dixon JS, Gray DF, Sabbat J. 2004. Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 351:1521-1531.
13. Mazumdar M, Smith A, Bacik J. 2003. Methods for categorizing a prognostic variable in a multivariable setting. Statist Med 22:559-571. (Pubitemid 36204178)
14. Molenberghs G, Verbeke G. 2005.Models for discrete longitudinal data. New York: Springer.
15. Pas SD, Fries E, De Man RA, Osterhaus AD, Niesters HG. 2000. Development of a quantitative real-time detection assay for hepatitis B virus DNA and comparison with two commercial assays. J Clin Microbiol 38:2897-2901. (Pubitemid 30640570)
16. Robins JM, Hernan MA, Brumback B. 2000. Marginal structural models and causal inference in epidemiology. Epidemiology (Cambridge, Mass) 11:550-560.
17. SAS. 2008. The GENMOD Procedure. Version 9.2. Cary, NC: SAS Institute Inc.
18. ter Borg MJ, van Zonneveld M, Zeuzem S, Senturk H, Akarca US, Simon C, Hansen BE, Haagmans BL, de Man RA, Schalm SW, Janssen HL. 2006. Patterns of viral decline during PEG-interferon alpha-2b therapy in HBeAg-positive chronic hepatitis B: Relation to treatment response. Hepatology 44:721-727.
19. ter Borg MJ, Hansen BE, Herrmann E, Zeuzem S, Cakaloglu Y, Karayalcin S, Flisiak R, van't Veen A, de Man RA, Schalm SW, Janssen HL, Haagmans BL. 2007. Modelling of early viral kinetics and pegylated interferon-alpha2b pharmacokinetics in patients with HBeag-positive chronic hepatitis B. Antivir Ther 12:1285-1294.
20. van Nunen AB, Hansen BE, Suh DJ, Lohr HF, Chemello L, Fontaine H, Heathcote J, Song BC, Janssen HL, de Man RA, Schalm SW. 2003. Durability of HBeAg seroconversion following antiviral therapy for chronic hepatitis B: Relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 52:420-424.
21. van Zonneveld M, Honkoop P, Hansen BE, Niesters HG, Murad SD, de Man RA, Schalm SW, Janssen HL. 2004. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 39:804-810.
22. van Zonneveld M, Flink HJ, Verhey E, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA, Hansen BE, Schalm SW, Janssen HL. 2005. The safety of pegylated interferon alpha-2b in the treatment of chronic hepatitis B: Predictive factors for dose reduction and treatment discontinuation. Aliment Pharmacol Ther 21:1163-1171.
23. Zoulim F, Perrillo R. 2008. Hepatitis B: Reflections on the current approach to antiviral therapy. J Hepatol 48:S2-19.